These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043 [TBL] [Abstract][Full Text] [Related]
3. Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: novel molecular diagnostic tools for a challenging differential diagnosis. Romagnani P; Lazzeri E; Mazzinghi B; Lasagni L; Guidi S; Bosi A; Cirami C; Salvadori M Am J Kidney Dis; 2005 Sep; 46(3):550-6. PubMed ID: 16129218 [TBL] [Abstract][Full Text] [Related]
4. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271 [TBL] [Abstract][Full Text] [Related]
10. Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Safdar A; Papadopoulous EB; Armstrong D Bone Marrow Transplant; 2002 Jun; 29(11):913-6. PubMed ID: 12080357 [TBL] [Abstract][Full Text] [Related]
11. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932 [TBL] [Abstract][Full Text] [Related]
12. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304 [TBL] [Abstract][Full Text] [Related]
13. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742 [TBL] [Abstract][Full Text] [Related]
14. [Membranous nephropathy following allogeneic peripheral blood stem cell transplantation in a boy with anaplastic large cell lymphoma]. Park YD; Hamada M; Higuchi B; Kishimoto T; Inagaki J; Nishiguchi M; Shimoyama H; Nakajima M; Nakagawa A; Yoshioka A Rinsho Ketsueki; 2004 Nov; 45(11):1193-7. PubMed ID: 15609686 [TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]